Gillette Christopher P. sold $47K of TRNS

Gillette Christopher P. sold 504 shares of TRANSCAT INC (TRNS) at $94.23 on 2026-08-07.

Original reporting
SEC EDGAR · Gillette Christopher P.
Published Aug 12, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TRNS
Neutral
medium confidence
Mentioned
$TRNS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRNSNeutralLow
01

Why it matters

The newest information is the specific open-market sale size, price, and resulting holdings after the transaction.

02

Market read

Traders may note insider selling, but the disclosed transaction value is small and lacks a fundamental catalyst.

03

What to watch

No 10b5-1 plan is stated, but the article does not provide context on prior holdings, compensation, or whether other insiders sold around the same time.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-08-12, reflecting the 2026-08-07 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Transcat (TRNS).

Company-level read

Ticker impact

$TRNSNeutralMedium confidence
Context

Transcat director Gillette Christopher P sold 504 shares in an open-market transaction for about $47.5K, per a newly filed Form 4.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing discloses the sale details (date, shares, price, post-transaction holdings) but provides no accompanying operational or financial catalyst.

Market effects

No clear sector read-through from a single small insider sale.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to company outlook (taxes, diversification, personal liquidity), especially with only 200 shares remaining post-sale.

Key entities

  • TRANSCAT INC

    Subject of the Form 4 insider transaction disclosure.

  • Gillette Christopher P.

    Director who sold 504 shares at $94.2345 on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TRNSMedAI 8/10

Transcat (TRNS) Q2 2027 Earnings Call Transcript

Transcat (TRNS) reported Q2 2027 revenue of $97.1M, up 18%, with service revenue growing 23% and distribution revenue up 10%. Gross profit increased 22%, and adjusted EBITDA grew 23% to $14.9M. The company cited strong demand in regulated end markets and strategic acquisitions, including Southeastern Biomedical Associates, as drivers of growth. Service gross margins expanded 220 basis points to 34.4%.

$TRNSMed

Transcat Q2 Earnings Call Highlights

Transcat (TRNS) reported Q2 growth in distribution revenue (10% to $32.3M) and adjusted EBITDA (23% to $14.9M). Management raised its fiscal 2027 service organic revenue growth outlook to low-double-digits and expects service gross-margin expansion. The company highlighted demand in regulated markets and completed an acquisition to expand its biomedical calibration footprint.

$TRNSMed

Transcat Reports Strong Fiscal Second Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Significant Service Gross Margin…

TRANSCAT INC (TRNS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE Transcat, Inc. 35 Vantage Point Drive • Rochester • NY • 14624 • Phone: (585) 352-7777 Transcat Reports Strong Fiscal Second Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Significant Service Gross Margin Expansion •